| The Efficacy of Intravaginal Electrical Stimulation in Women With Idiopathic Overactive Bladder (NCT05416450) | Pamukkale University | 2022-07-01 |
| INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder (NCT05309993) | University of New Mexico | 2022-06-30 |
| Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder (NCT06479720) | Mackay Memorial Hospital | 2022-06-16 |
| Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity (NCT06197295) | Mackay Memorial Hospital | 2022-06-16 |
| INTIBIA Pivotal Study (NCT05250908) | Coloplast A/S | 2022-03-07 |
| Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity (NCT05968885) | Mackay Memorial Hospital | 2021-10-01 |
| BOTOX® at the Time of Prolapse Surgery for OAB (NCT04807920) | Walter Reed National Military Medical Center | 2021-09-23 |
| Direct Full-stage Implantation of Sacral Neuromodulation (NCT03697954) | Loma Linda University | 2021-05-01 |
| Targeting Microbiota in Female Overactive Bladder Syndrome (NCT05328011) | Medical University of Vienna | 2020-12-01 |
| Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis (NCT04528784) | University of Limerick | 2020-10-14 |
| Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms (NCT04420533) | Chang Gung Memorial Hospital | 2020-06-05 |
| Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A (NCT04305743) | University of South Florida | 2019-10-09 |
| Pilot Phase for an Acute Evaluation of a Non-Implantable Electrical Continence Device (NCT04001426) | FemPulse Corporation | 2019-04-04 |
| FemPulse Therapy for Overactive Bladder in Women (NCT03784170) | FemPulse Corporation | 2018-12-11 |
| Laser Therapy for Treatment of Urogenital Symptoms in Women (NCT03681678) | Corewell Health East | 2018-10-08 |
| OnabotulinumtoxinA Bladder Injection Study (NCT03523091) | Corewell Health East | 2018-08-08 |
| Fluids Affecting Bladder Urgency and Lower Urinary Symptoms (NCT03625492) | University of Michigan | 2018-08-07 |
| Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC) (NCT03043287) | Allergan | 2017-05-12 |
| FemPulse Therapy First-in-Human Experience (NCT03874637) | FemPulse Corporation | 2017-02-14 |
| Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence (NCT03052764) | Allergan | 2016-12-12 |
| Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NCT02849418) | GlaxoSmithKline | 2016-10-11 |
| Fesoterodine on Urgency Episodes in Parkinson's Disease Population (NCT02385500) | Sir Mortimer B. Davis - Jewish General Hospital | 2016-09-01 |
| Electrostimulation in the Treatment of Idiopathic Overactive Bladder (NCT03519126) | Janaina Mayer de Oliveira Nunes | 2016-04-19 |
| Urodynamic Testing: Can we Improve Patient Experience? (NCT02742389) | Boston Urogynecology Associates | 2016-04-01 |
| Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder (NCT02673047) | Allergan | 2016-02-01 |
| Brain Areas Involved in Bladder Filling and Contraction (NCT02477241) | Maastricht University Medical Center | 2015-09-01 |
| Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder (NCT02557971) | Allergan | 2015-08-01 |
| Overactive Bladder Education (NCT02505607) | Hartford Hospital | 2015-07-01 |
| Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement (NCT02462837) | Southern Illinois University | 2015-05-01 |
| A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) (NCT02386072) | Astellas Scientific & Medical Affairs, Inc. | 2015-01-05 |
| IVES for Treatment of UUI and OAB (NCT02992509) | Loma Linda University | 2014-12-01 |
| A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice (NCT02320773) | Astellas Pharma Europe Ltd. | 2014-11-25 |
| A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics (NCT02087098) | Astellas Pharma Europe B.V. | 2014-06-01 |
| An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder (NCT02161159) | Allergan | 2014-06-01 |
| Comparisons of Urodynamic, Bladder Diary, Quality of Life Parameters Between OAB-wet and OAB-dry Female Patients (NCT03560778) | National Taiwan University Hospital | 2014-05-05 |
| A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (NCT02045862) | Astellas Pharma Europe B.V. | 2014-03-17 |
| Effects of TENS in Autonomous System in Women With Overactive Bladder (NCT02456441) | Federal University of Health Science of Porto Alegre | 2014-03-01 |
| Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea (NCT02010788) | Allergan | 2014-02-01 |
| Use of Medium Frequency Electrotherapy in the Treatment of OAB, LUTS and Pelvic Pain (NCT03520166) | Fisioterapia Pélvica Avanzada Madrid, SRL | 2014-01-10 |
| This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (NCT01972841) | Astellas Pharma Europe B.V. | 2013-11-05 |
| A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (NCT01908829) | Astellas Pharma Europe Ltd. | 2013-07-10 |
| The Effect of Anticholinergics on Cognitive Function in the Elderly (NCT01922115) | University of North Carolina, Chapel Hill | 2013-06-01 |
| Behavioural Therapy Program for Female Overactive Bladder (NCT02701010) | Saglik Bilimleri Universitesi Gulhane Tip Fakultesi | 2012-11-01 |
| Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder (NCT01558856) | Centre Hospitalier Universitaire de Nīmes | 2012-10-23 |
| A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 (NCT01655069) | Astellas Pharma Europe B.V. | 2012-10-04 |
| Prevention of Bladder Dysfunction in Acute Spinal Cord Injury (NCT01698138) | Oslo University Hospital | 2012-09-01 |
| Management of the Idiopathic Overactive Bladder With Botulinum Toxin: Systematic Review (NCT01750645) | Clínica Infantil Colsubsidio | 2012-07-01 |
| A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug (NCT01565707) | Astellas Pharma Europe B.V. | 2012-06-07 |
| A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers (NCT01566760) | Pfizer | 2012-05-01 |
| Study of Overactive Bladder in Women With Prolapse (NCT01540214) | Radboud University Medical Center | 2012-02-01 |
| Pharmacokinetics and Relative Bioavailability Study (NCT01521767) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2011-10-01 |
| A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. (NCT01302054) | Pfizer | 2011-05-01 |
| A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008) (NCT01314872) | Merck Sharp & Dohme LLC | 2011-03-31 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (NCT01340027) | Astellas Pharma Europe B.V. | 2011-03-29 |
| Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy (NCT01091519) | Pfizer | 2010-12-01 |
| Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents (NCT01262391) | Astellas Pharma Inc | 2010-10-20 |
| Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence (NCT01194999) | Barrie Urology Associates | 2010-10-01 |
| Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms (NCT01381120) | Barrie Urology Associates | 2010-10-01 |
| Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence (NCT01157377) | Allergan | 2010-10-01 |
| Cohort Study: Perceptual Urge Sensation (NCT00971646) | Maastricht University Medical Center | 2010-06-01 |
| Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder (NCT01054222) | Pfizer | 2010-05-01 |
| A Study of YM178 in Subjects With Symptoms of Overactive Bladder (NCT01043666) | Astellas Pharma Inc | 2009-12-21 |
| Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients (NCT00985387) | Astellas Pharma Inc | 2009-08-01 |
| The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects (NCT00914667) | Pfizer | 2009-07-01 |
| Age-specific Prevalence and Comparisons of UDS and Bladder Diary Between OAB-wet and -Dry Women (NCT03807024) | National Taiwan University Hospital | 2009-07-01 |
| A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (NCT00912964) | Astellas Pharma Inc | 2009-04-28 |
| Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency (NCT00979472) | Asan Medical Center | 2009-04-01 |
| UK Study Assessing Flexible Dose Fesoterodine in Adults (NCT00806494) | Pfizer | 2009-02-01 |
| Modified Extension Study to the SUmiT Trial: Evaluation of Long Term Therapy With Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder Symptoms (NCT00928395) | Uroplasty, Inc | 2009-01-01 |
| Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder (NCT00805779) | EMKinetics, Inc | 2008-12-01 |
| A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients (NCT00840645) | Astellas Pharma Inc | 2008-12-01 |
| A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031 (NCT00814736) | Pfizer | 2008-08-01 |
| 516-BOTOX Urinary Incontinence Detrusor (NCT00850733) | Veterans Medical Research Foundation | 2008-08-01 |
| A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder (NCT00699049) | KYU-SUNG LEE | 2008-06-01 |
| A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder. (NCT00798434) | Pfizer | 2008-06-01 |
| Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (NCT00689104) | Astellas Pharma Inc | 2008-04-28 |
| A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (NCT00662909) | Astellas Pharma Inc | 2008-03-28 |
| A Study of YM178 in Patients With Symptomatic Overactive Bladder (NCT00527033) | Astellas Pharma Inc | 2007-09-11 |
| An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants (NCT00613327) | Janssen Korea, Ltd., Korea | 2007-09-01 |
| Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life (NCT00573508) | Astellas Pharma Inc | 2007-08-01 |
| Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan). (NCT00795509) | Pfizer | 2007-08-01 |
| Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder (NCT00479505) | Pfizer | 2007-06-01 |
| A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients (NCT00368706) | Astellas Pharma Inc | 2006-09-01 |
| Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms (NCT00463541) | Astellas Pharma Inc | 2004-06-01 |
| Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder (NCT00454740) | Astellas Pharma Inc | 2004-06-01 |
| A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB) (NCT00454896) | Astellas Pharma Inc | 2004-05-01 |
| Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder (NCT01604928) | Astellas Pharma Europe B.V. | 2004-04-05 |
| Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms (NCT00801944) | Astellas Pharma Inc | 2004-04-01 |
| A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder. (NCT00645281) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2004-03-01 |
| A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring (NCT00646880) | Pfizer | 2003-03-01 |